Sanofi’s Dupixent (dupilumab) Receives Health Canada’s Approval for Adults and Adolescent Patients Aged ≥12 Years with Eosinophilic Esophagitis
- Health Canada has approved Dupixent for patients aged ≥12yrs. The P-III trial (LIBERTY-EoE-TREET) consists of parts A & B evaluating Dupixent (300mg, qw) vs PBO in 39 & 79 patients
- Parts A of the trial met co-1EPs & all 2EPs and showed improved structural & histologic measures while rapidly improving the ability to swallow. Additional improvements in disease severity & extent, as well as normalized gene expression associated with type 2 inflammation, were reported
- Part B showed improvement in the signs & symptoms @24wks. & the safety results were consistent with the known safety profile of Dupixent in its approved indications. Dupixent is a fully human mAb inhibiting signaling of IL-4 & IL-13 pathways
Ref: Newswire | Image: Sanofi
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.